A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1 Meeting Abstract
| Authors: | Iyer, G.; Ebi, H.; Cook, N.; Gao, X.; Kitano, S.; Matsubara, N.; Reimers, M. A.; Siefker-Radtke, A. O.; Kim, M.; Galsky, M. D.; Robbrecht, D. G.; Guo, J.; Eigl, B. J.; Schaverien, C.; Butts, B.; Yuen, E.; Szymczak, S.; Zhao, X.; Widau, R. C.; Drakaki, A. |
| Abstract Title: | A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1 |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454740400007 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.662 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 662 -- Source: Wos |
